RxDoctor Payments Data

Fuad Elkhoury, MD

Urology · Santa Monica, CANPI 1689092728

Payments from drug & device makers

$27,208in general payments, 2019–2025

Across 81 payments — averaging $335.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$21K
  • Boston Scientific$6K
  • AbbVie$325
  • Astellas Pharma US Inc$161
  • Sumitomo Pharma America, Inc.$58
  • Procept Biorobotics Corporation$49
  • plus $363 from 12 others

What the payments were for

  • Consulting fees$18,61268%
  • Grants$5,00018%
  • Travel & lodging$1,7676%
  • Food & beverage$1,7646%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,208 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$253,624
Medicare patients
441
Services billed
3,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron51$35,402
MyrbetriqMirabegron31$28,666
Trospium Chloride ErTrospium Chloride39$12,396
Tamsulosin Hcl533$6,960
Finasteride214$2,771
Potassium Citrate ErPotassium Citrate37$2,126
Silodosin15$1,417
Dutasteride19$824
Cephalexin114$745
Alfuzosin Hcl ErAlfuzosin Hcl30$627
Tadalafil22$626
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst38$492
Diclofenac Sodium116$462
Sildenafil Citrate41$376
Oxybutynin Chloride ErOxybutynin Chloride36$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$58$35,40251 claims
Astellas Pharma US IncMyrbetriq$161$28,66631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →